An official website of the United States government

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search Blueprint

Main navigation

Funding & Research
- Funding Opportunities
- Blueprint Research Initiatives
Human Connectome
- Connectome Programs
- Connectome Projects
Neurotherapeutics & MedTech
Training
Resource & Tools
- Blueprint Resources & Tools Library
About

Home
About
EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain

EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain

Thursday, October 10, 2019

Image

EicOsis advancement of EC5026 into clinical trials has been funded as part of the Blueprint Neurotherapeutics Network (BPN) of the NIH Blueprint for Neuroscience Research. Read the full press release here.

About

NIH Blueprint Overview
Diversity and Scientific Excellence
Participating NIH Institutes
News
Events

Did you find the content you were looking for?

Yes, I did find the content I was looking for No, I did not find the content I was looking for

Please rate how easy it was to navigate the NINDS website

Very easy to navigate Easy to navigate Neutral Difficult to navigate Very difficult to navigate

Thank you for letting us know! Any other feedback?

This site is protected by reCAPTCHA and the Google Privacy Policyand Terms of Serviceapply.

Last reviewed on June 24, 2022

Footer Menu

Contact Us
Freedom of Information Act (FOIA)
NIH Web Policies & Notices

Tools

Download Adobe Plug-In

Department of Health & Human Services
National Institutes of Health
USA.gov
Vulnerability Disclosure Policy